Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease

作者：Colak Yasar^*; Senates Ebubekir; Ozturk Oguzhan; Doganay Hamdi Levent; Coskunpinar Ender; Oltulu Yasemin Musteri; Eren Ayse; Sahin Onder; Ozkanli Seyma; Enc Feruze Yilmaz; Ulasoglu Celal; Tuncer Ilyas

来源：Metabolic Syndrome and Related Disorders, 2012, 10(2): 103-109.

DOI：10.1089/met.2011.0111

Background: Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome and is one of the most common causes of chronic liver disease, worldwide. Lipoprotein-associated phospholipase A2 (Lp-PLA2) was recently characterized as a novel inflammatory biomarker that is correlated with several components constituting the metabolic syndrome. %26lt;br%26gt;Methods: In this study, we determined the serum levels of Lp-PLA2 in patients with definite nonalcoholic steatohepatitis (NASH, n = 25), borderline NASH (n = 22), simple fatty liver (n = 10), and healthy controls without evidence of liver disease (n = 38). The levels of Lp-PLA2 were measured by enzyme-linked immunosorbent assay and compared in the four study groups. Moreover, concentrations of Lp-PLA2 were assessed in relation to the general characteristics of the study participants and the results of liver biopsy. %26lt;br%26gt;Results: Concentrations of Lp-PLA2 were significantly higher in patients with definite NASH (161.8 +/- 0.9 mu g/L, P %26lt; 0.001), borderline NASH (135.4 +/- 47.7 mu g/L, P = 0.001), and simple fatty liver (132.4 +/- 46.2 mu g/L, P = 0.042) compared with healthy controls (86.2 +/- 40.7 mu g/L). Furthermore, the serum Lp-PLA2 level was strongly associated to histological steatosis scores in patients with NAFLD (beta = 0.32, t = 2.50, P = 0.016). %26lt;br%26gt;Conclusion: Although subject to future confirmation, our data suggest that Lp-PLA2 levels are elevated in NAFLD.

• 出版日期2012-4